[Eprosartan mesylate in controlling of blood pressure in patients with ischemic stroke].

Abstract

In 20 patients with ischemic stroke and moderate or severe arterial hypertension the effectiveness of eprosartan mesilat (Teveten, Solway Farma, Germany) for a period of 6 months was studied. Patients received 600 mg of eprosartan mesilat daily and in 4 cases hydrochlortyaside was also added. Monotherapy with eprosartan mesilat was effective in all patients with moderate arterial hypertension and in 43.6% in patients with severe arterial hypertension. Therapy with eprosartan mesilat was associated with significant hypotensive effect (more evident in patients with high systolic blood pressure), improvement in 24-hour blood pressure profile and quality of life, and lower probability of secondary stroke. Side effects were not observed.

• Authors: M Iu Martynov, A N Boĭko, E B Petukhov, V P Berezov, A N Maskarov, E I Gusev
• Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 102 Issue 4 Pg. 26-30 ( 2002) ISSN: 1997-7298 [Print] Russia (Federation)
• Vernacular Title: Primenenie éprosartana mezilata dlia kontrolia urovnia arterial'nogo davleniia u bol'nykh s ishemicheskim insul'tom.
• PMID: 12001661 (Publication Type: Journal Article)

Chemical References

• Antihypertensive Agents
• Imidazoles
• Thiophenes
• eprosartan mesylate dihydrate

Topics

• Aged
• Antihypertensive Agents (administration & dosage, therapeutic use)
• Brain (blood supply)
• Brain Ischemia (etiology)
• Cerebrovascular Circulation (physiology)
• Female
• Humans
• Hypertension (complications, diagnosis, prevention & control)
• Imidazoles (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Thiophenes (administration & dosage, therapeutic use)